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Background: Kruppel-like factor 4 (KLF4) induces tumorigenesis or suppresses tumor growth in a tissue-dependent
manner. However, the roles of KLF4 in hematological malignancies and the mechanisms of action are not fully
understood.
Methods: Inducible KLF4-overexpression Jurkat cell line combined with mouse models bearing cell-derived xenografts
and primary T-cell acute lymphoblastic leukemia (T-ALL) cells from four patients were used to assess the functional role
of KLF4 in T-ALL cells in vitro and in vivo. A genome-wide RNA-seq analysis was conducted to identify genes regulated
by KLF4 in T-ALL cells. Chromatin immunoprecipitation (ChIP) PCR was used to determine direct binding sites of KLF4
in T-ALL cells.
Results: Here we reveal that KLF4 induced apoptosis through the BCL2/BCLXL pathway in human T-ALL cell lines
and primary T-ALL specimens. In consistence, mice engrafted with KLF4-overexpressing T-ALL cells exhibited prolonged
survival. Interestingly, the KLF4-induced apoptosis in T-ALL cells was compromised in xenografts but the invasion
capacity of KLF4-expressing T-ALL cells to hosts was dramatically dampened. We found that KLF4 overexpression
inhibited T cell-associated genes including NOTCH1, BCL11B, GATA3, and TCF7. Further mechanistic studies revealed
that KLF4 directly bound to the promoters of NOTCH1, BCL2, and CXCR4 and suppressed their expression. Additionally,
KLF4 induced SUMOylation and degradation of BCL11B.
Conclusions: These results suggest that KLF4 as a major transcription factor that suppresses the expression of
T-cell associated genes, thus inhibiting T-ALL progression.
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KLF4, also known as GKLF (gut KLF), is a member of
the KLF zinc finger-containing transcription factor family
[1,2]. Klf4 together with Oct4, Sox2, and c-Myc are widely
referred to as ‘Yamanaka factors’ enforced expression of
which makes adult cells reprogram into pluripotent stem
cells [3]. Consistently, the expression levels of Klf4, Sox2,
and Oct4 may need to be decreased during the differen-
tiation of pluripotent cells [4]. Klf4 has critical function
in development. Mice homozygous for a null mutation
in Klf4 die within a day after birth and show defects in
epidermis and colonic epithelial cell differentiation [5].
A recent study reports that the downregulation of Klf4
is required for T cell lineage commitment in mice and
Klf4 overexpression blocks T cell development primarily
at early stage through suppressing the transcription of sev-
eral genes that are crucial for early T cell development [6].
T cell development involves progenitor homing and
lineage specification and commitment [7]. During early
T cell development, several key T cell genes, including
Notch1, Bcl11b, Gata3, and Tcf7 are upregulated [8-11].
T cell development is tightly regulated by key transcrip-
tion factors, such as Notch1 [12] and Bcl11b [13]. One
important mechanism in T cell development is small
ubiquitin-like modifier (SUMO) modification because
several T cell-associated transcription factors are regu-
lated by SUMO-specific proteases [14]. A previous study
identified two SUMO acceptor sites in Bcl11b and dem-
onstrated that prolonged sumoylation resulted in deg-
radation of Bcl11b [15].
T-ALL is thought to result from malignant thymocytes
that arise at defined stages of T cell differentiation.
Moreover, the expression of certain oncogenes or mu-
tated T cell-specific genes has been closely linked to de-
velopmental arrest at particular stages of normal T cell
development [16]. Activating mutations of NOTCH1 were
identified in roughly 60% of primary human T-ALLs [17].
Murine T-ALLs studies revealed the presence of acquired
gain-of-function Notch1 mutations at frequencies varying
from 30% to 80%, depending on the genetic model [18]. In
addition, BCL11B mutations are associated with T cell
proliferative disorders. The inversion inv(14)(q11.2q32.31)
disrupting the BCL11B locus has been identified in two
cases of T-ALL [19], and monoallelic BCL11B deletions or
missense mutations were detected in 9% of T-ALL cases
[20]. KLF4 has obtained attention as a negative regulator
in T-ALL, because DNA methylation of KLF4 gene makes
its silencing in T-ALL cells and KLF4 overexpression
induces apoptosis in ATL-43 T cell line [21]. A recent
study identified novel mutations in 3′ untranslated region
(UTR) of the KLF4 gene that resulted in loss of miR-2909-
mediated regulation in pediatric T-ALL [22]. However, the
molecular mechanisms involved in KLF4-induced apop-
tosis in T-ALL have not been well characterized.To systematically analyze the genes regulated by KLF4
in T-ALL, we have performed the genome-wide RNA-seq
analysis in KLF4 overexpressing Jurkat cells engrafted in
immune-compromised NOD-SCID mice. As a negative
regulator in human T-ALL in vitro and in vivo, KLF4 was
shown to inhibit a variety of T-cell associated genes by
directly binding to NOTCH1 promoter and inducing
SUMOylation of BCL11B. Our study thus establishes
KLF4 as a critical transcriptional factor directly sup-
pressing T-cell associated transcription factors such as
NOTCH1 and BCL11B in malignant T cells.
Results
Enforced KLF4 expression induces apoptosis in Jurkat cells
through the BCL2/BCLXL pathway
To investigate the function of KLF4 in Jurkat cells, the
TRE-KLF4 and TRE-empty Jurkat cell lines that were
constitutively GFP+ were established (Additional files 1
and 2: Figures S1-S2). In TRE-KLF4 cells, the KLF4
overexpression was induced by Doxycycline (Dox) treat-
ment (Figure 1a-b). Dox treatment did not change the
expression levels of KLF4 and genes that are related to
apoptosis and T cell development in WT Jurkat cells
(Additional files 1 and 2: Figure S3). Indeed, we detected
massive cell death in Dox-induced TRE-KLF4 cells at
48 hours after Dox treatment, concomitant with the
increase of CASP3 (Figure 1b) and accumulation of
apoptotic cells, whereas TRE-KLF4 cells without Dox
treatment and Dox-treated TRE-empty cells grew well
(Figure 1c-d). The protein degradation during cell
death might explain why the KLF4 protein level de-
creased at 50 hours after Dox treatment (Figure 1b). To
validate whether KLF4 overexpression induced apop-
tosis by affecting Caspase activities in Jurkat cells, we
treated the Dox-induced TRE-KLF4 cells with Z-VAD-
FMK, a pan caspase inhibitor, in an attempt to rescue
Jurkat cells from KLF4-mediated apoptosis. Indeed, we
found that Z-VAD-FMK treatments reduced the apoptotic
rate of Jurkat cells with KLF4 overexpression (Figure 1d).
Furthermore, we detected the catalytic activity of CASP3
(Additional files 1 and 2: Figure S4) and the decrease of
mitochondrial membrane potential in KLF4 overex-
pressing Jurkat cells but not in TRE-KLF4 cells without
Dox treatment or WT Jurkat cells with Dox treatment
(Additional files 1 and 2: Figure S5). These results sug-
gested that the BCL2 pathway was involved in KLF4-
induced apoptosis in Jurkat cells.
Upon Dox-induced KLF4 overexpression in Jurkat
cells, we measured the expression levels of several genes
related to apoptosis at different time points and ob-
served that TRAIL expression was upregulated after Dox
treatment, whereas the expression of BCL2 was sup-
pressed, and BCLXL expression remained unchanged
(Figure 1e-f ). To evaluate whether BCL2 or BCLXL
Figure 1 (See legend on next page.)
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Figure 1 Enforced expression of KLF4 induces apoptosis and suppresses BCL2 in Jurkat cells. (a) Quantification of KLF4 mRNA levels in
TRE-KLF4 Jurkat cells. The results were normalized to the GAPDH mRNA levels and are represented as the mean +/- SEM (n = 3). (b) Western blot
analysis of KLF4, CASP3, and ACTIN protein levels in TRE-KLF4 Jurkat cells. (c) TRE-KLF4 Jurkat cell cultures with (black squares) or without (black
diamonds) Dox treatment. TRE-empty Jurkat cell cultures with (grey triangles) Dox treatment. Data are represented as the mean +/- SEM (n = 3).
(d) TRE-KLF4 Jurkat cells were treated (+Dox) or not (-Dox) with Dox. Z-VAD-FMK (I) and Dox were added at the same time (Dox + I). 48 hours
later, cells were subjected to apoptosis assays. Top, representative of flow cytometry profiles of Jurkat cells in apoptosis assays. Bottom, summary
of percentages of apoptotic cells (Annexin-V + 7-AAD+) from three independent apoptosis assays. Data are represented as the mean +/- SEM.
**P ≤ 0.01 versus bar 1 (for bar 2), *** P ≤ 0.001 versus bar 1 (for bars 3 and 4). (e) Quantitative RT-PCR analysis of the expression of selected
genes in TRE-KLF4 cells. Data are shown as the mean +/- SEM. (f) Western blot analysis of the protein levels of selected apoptosis genes in TRE-KLF4
cells 48 hours post Dox treatment. (g) Jurkat cells were transfected with indicated lentiviruses. 48 hours later, GFP+ cells were subjected to apoptosis
assays. Top, representative of flow cytometry profiles of Jurkat cells in apoptosis assays. Bottom, summary of percentages of apoptotic cells from three
independent assays. Data are represented as the mean +/- SEM. For Annexin-V + 7-AAD+, ***P ≤ 0.001 versus bar 1 (for bars 2-4); For Annexin-V+,
***P ≤ 0.001 versus bar 1 (for bars 2-4).
Figure 2 Effects of KLF4 overexpression on primary T-ALL cells.
Primary T-ALL patient BM samples (n = 3) were transduced with
either KLF4-GFP (KLF4) or GFP (CTL) lentiviruses. 72 hours after
transduction, GFP+ cells were subjected to apoptosis assays as
measured by Annexin-V binding and 7-AAD staining. Top, representative
of flow cytometry profiles of primary T-ALL cells in apoptosis assays.
Bottom, summary of percentages of apoptotic cells (Annexin-V + 7-AAD+)
from three independent apoptosis assays. Data are represented as
the mean +/- SEM. *P ≤ 0.05 versus bar 1 (for bar 2).
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vectors encoding KLF4-BCL2 and KLF4-BCLXL were
constructed and transduced into Jurkat cells (Additional
files 1 and 2: Figure S1). Co-expression of BCL2 or
BCLXL did not affect KLF4 expression levels in Jurkat
cells (Additional files 1 and 2: Figure S6). Jurkat cells
transduced with the KLF4 lentivirus demonstrated an
apoptotic cell (Annexin-V+, 7-AAD+) frequency of
19.5%, whereas only 0.9% of cells transduced with the
KLF4-BCL2 lentivirus underwent apoptosis (Figure 1g).
Similarly, the percentage of apoptotic population was re-
duced to 3.3% when BCLXL was co-expressed with
KLF4 (Figure 1g). Thus, enforced expression of BCL2 or
BCLXL almost completely rescued Jurkat cells from
apoptosis upon KLF4 overexpression, indicating that
KLF4 induced apoptosis by suppressing the BCL2 path-
way in T-ALL cells.
To exclude the possibility that the effects of KLF4 on
Jurkat cells were cell line-specific, we next tested
whether KLF4 could induce apoptosis in MOLT4 or
CCRF-CEM cells, which are two γ-secretase inhibitors
(GSI)-resistant T-ALL cell lines [22] and expressed min-
imal KLF4 (Additional files 1 and 2: Figure S7). Both cell
lines underwent apoptosis upon KLF4 overexpression
(Additional files 1 and 2: Figures S8-S9). Furthermore,
we confirmed that KLF4 overexpression induced apop-
tosis in CUTLL1 cells that are sensitive to GSI and did
not express KLF4 either [22] (Additional files 1 and 2:
Figures S7 and S10). In contrast, KLF4 overexpression
did not induce apoptosis either in RL (Additional files 1
and 2: Figure S11), a B cell lymphoma cell line [23], or
in K562 (Additional files 1 and 2: Figure S12), a myeloid
leukemia cell line [24].
KLF4 overexpression induces apoptosis in primary T-ALLs
To validate whether KLF4 induced apoptosis in primary
T-ALL cells, we transduced a KLF4-GFP lentivirus into
primary T-ALL samples from four patients, in which
more than 75% mononuclear BM cells were T-ALL cells
(Additional files 1 and 2: Figure S13). KLF4 overexpressioncaused elevated apoptosis in these cells compared to GFP-
transduced controls (Figure 2). To investigate whether
there were any mutations in the 3′ UTR of the KLF4
genes that were previously identified in pediatric T-ALL
[25], we sequenced the same regions in Jurkat and the two
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(Additional files 1 and 2: Figure S14). These results dem-
onstrate that KLF4 overexpression could induce apoptosis
in primary T-ALL cells in vitro.
KLF4 overexpression reduces aggression of Jurkat cells
in vivo
To examine the effect of KLF4 overexpression on Jurkat
cells in vivo, we injected TRE-KLF4 cells and TRE-
empty cells into immunodeficient NOD-SCID mice and
started Dox treatments one day after injection of JurkatFigure 3 Overexpression of KLF4 in Jurkat cells in vivo. (a) Experiment
Jurkat cells in which KLF4 expression was induced by Dox treatment were
separated into two groups (n = 15) with Dox treatment or without Dox treatm
Jurkat cells and were subsequently treated with Dox. The three groups of mic
every two days. (b) Survival curves for the NOD/SCID mice injected with TRE-K
Dox-treated mice with injection of TRE-KLF4 Jurkat cells (KLF4 + Dox); Blue do
(KLF4-Dox); Green dots represent Dox-treated mice with injection of TRE-e
four mice from each group were culled for detection of Jurkat cells. Represen
blood from the three groups of mice described in b. (d) Summary of perc
from the three groups of mice described in b. (e) Summary of absolute nu
groups of mice described in b.cells (Figure 3a). The mice injected with TRE-KLF4 cells
without Dox treatment and the mice injected with TRE-
empty cells with Dox treatment died within 25 days,
while all of the mice that were injected with TRE-KLF4
cells and received Dox treatment started to die two
months after injection of Jurkat cells (Figure 3b). To our
surprise, the percentages of Jurkat cells in the Dox-
treated mice were similar to than that in Dox-untreated
mice (Figure 3c-d). In addition, the sizes and cellularity
of the spleens in Dox-treated mice were significantly
larger than that in Dox-untreated mice (Additional files 1al design for studying KLF4 function in Jurkat cells in vivo. TRE-KLF4
intravenously injected into NOD-SCID mice. The injected mice were
ent. In the third group, NOD-SCID mice were injected with TRE-empty
e were monitored for tumors. Dox was intraperitoneally administered
LF4 Jurkat cells. 15 mice were used in each group. Red dots represent
ts represent mice injected with TRE-KLF4 cells without Dox treatment
mpty cells (CTL + Dox). (c) Two weeks after injection of Jurkat cells,
tative FACS profiles of mononuclear cells of spleen, BM, and peripheral
entages of TRE-KLF4 Jurkat cells in spleen, BM, and peripheral blood
mbers of TRE-KLF4 Jurkat cells in spleen and BM from the three
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cells in the spleens of Dox-treated mice were significantly
higher than that in Dox-untreated mice (Figure 3e). In
addition, cell cycle analysis showed that KLF4 overexpres-
sion did not alter the proliferation of Jurkat cells in vivo
(Additional files 1 and 2: Figure S16). Taken together,
these results indicated that Jurkat cells with KLF4 overex-
pression survived in vivo but their aggression to hosts was
reduced.
We then compared the gene expression profile of
TRE-KLF4 Jurkat cells from Dox-treated mice to that
from Dox-untreated mice by RNA-sequencing (RNA-
seq) analyses. About 11,000 of the 20860 Refseq genes
were detectably expressed (R1 reads per kilo-base exon
model per-million reads [RPKM]) in each population
after murine transcripts were excluded (Figure 4a).
Additional file 3: Table S2 contains a list of genes with
greater-than-two fold difference in expression between
Dox-treated Jurkat cells and Dox-untreated Jurkat cells.
We confirmed the RNA-seq results by quantitative re-
verse transcription PCR (qRT-PCR) to measure the ex-
pression levels of KLF4, BID [26], S100A6 [27], FAT1
[28], FN1 [29], CKAP4 [30], genes known to play im-
portant roles during apoptosis or cell proliferation
(Additional files 1 and 2: Figure S17). With KLF4 over-
expression, pro-apoptotic genes including BID [26] and
BIK [31] decreased, while genes involved in anti-apoptosis
were upregulated (Figure 4b). Interestingly, CCR7 [32] that
regulates CNS infiltration in T-ALL and CXCR4 [33,34],
which is essential for stem cell and leukemia cell
localization were both repressed upon KLF4 overex-
pression in Jurkat cells (Figure 4b). Furthermore, TMBIM4
that promotes cell adhesion and migration was down-
regulated after KLF4 was overexpressed [35]. FAT1, a
therapeutic target in high-risk preB-ALL, was also sup-
pressed upon KLF4 overexpression [28]. Conversely,
cell adhesion proteins including FN1 [36] and THBS1
[37] were upregulated after KLF4 was overexpressed
(Figure 4b). It was surprising to find that all T cell-
associated genes, including T cell specific transcription
factors (BCL11B, TCF7, and GATA3), T cell surface
markers (CD1d, CD3E, and CD28), and TCR-related
genes (ZAP70, RAG1, RAG2, and ADA) were uniformly
silenced in Jurkat cells upon KLF4 overexpression
(Figure 4b). Interestingly, TAL1, of which aberrant acti-
vation is involved in up to 60% of T-ALL cases [38], was
severely repressed in Jurkat cells upon KLF4 overex-
pression (Figure 4b). In contrast, expression of BCL11A
[39], CEBPB [40], and GATA2 [41] that are important
for B, or myeloid cell lineages were upregulated upon
KLF4 overexpression (Figure 4b). These results suggested
that the tissue homing capacity of Jurkat cells was com-
promised and T cell transcription program of the T-ALL
cell line was disrupted when KLF4 was overexpressed.Identification of KLF4 target genes in T-ALL
To validate the results of RNA-seq analysis, we trans-
duced a KLF4-GFP lentivirus and a GFP-only lentivirus as
control into Jurkat cells respectively (Additional files 1
and 2: Figures S1 and S18). Forty-eight hours after enfor-
cing the expression of KLF4, we observed that mRNA
and protein levels of T cell-associated genes, including
NOTCH1, BCL11B, TCF7, and GATA3, decreased sig-
nificantly upon KLF4 overexpression (Figure 4c-d). To
detect potential direct KLF4 target genes in T-ALL, we
selected KLF4-repressed candidate genes identified
from RNA-seq analysis (Additional file 3: Table S2) that
contained KLF4 motif in the promoter regions [42] or
were identified by ChIP-seq analysis as direct Klf4
target genes in a mammary epithelial cell line [43] for
ChIP validation. Chromatin immunoprecipitates pre-
pared from Jurkat cells, in which the transduction effi-
ciencies of KLF4-GFP lentivirus were about 40%
(Additional files 1 and 2: Figure S18), revealed that
KLF4 associated with putative binding sites in the
promoter regions of NOTCH1, CXCR4, and BCL2
(Figure 4e). In contrast, KLF4 did not associated with
DNA fragments in the promoters of βACTIN (Figure 4e).
Taken together, these data suggest that KLF4 downregu-
lated NOTCH1, CXCR4, and BCL2 directly.
KLF4 induces the SUMOylation and degradation of BCL11B
Although the transcription levels of BCL11B decreased
50% upon KLF4 overexpression (Figure 4c), the levels of
BCL11B protein significantly decreased in TRE-KLF4
Jurkat cells 72 hours after the induction of KLF4 overex-
pression (Figure 4d), while BCL11B protein levels did
not change in wild-type Jurkat cells after Dox treatment
(Additional files 1 and 2: Figure S19). These results
drove us to investigate whether KLF4 affected BCL11B
post-translation. SUMOylation is commonly associated
with protein degradation; therefore, we speculated that
the overexpression of KLF4 might induce the SUMOy-
lation of BCL11B, leading to the degradation of BCL11B
protein. We observed SUMOylation of BCL11B at
30 hours after KLF4 was overexpressed in Jurkat cells
(Figure 5a). As calyculin A can potently inhibit SUMOy-
lation [15], we found that the SUMOylation of BCL11B
was gradually suppressed following calyculin A treat-
ment (Figure 5b). Furthermore, calyculin A partially
rescued Jurkat cells from KLF4-induced apoptosis
(Figure 5c). Because SUMOylation triggers a secondary
signal mediating ubiquitin-dependent degradation by
the proteasome [14], we further validated that MG132,
a potent proteasome inhibitor [44], could also rescue
Jurkat cells from KLF4-induced apoptosis (Figure 5d).
Taken together, these results suggested that KLF4 over-
expression induced BCL11B protein degradation by
SUMOylation.
Figure 4 Downstream targets of KLF4 in T-ALL. (a) Scatter plots of Dox-treated versus Dox-untreated TRE-KLF4 Jurkat transcriptomes.
(b) Unsupervised hierarchical cluster analysis of expression levels of 32 genes that are important for apoptosis, metastasis, T cell, or non-T cell
lineages in Dox-treated and Dox-untreated TRE-KLF4 Jurkat cells (red, increased expression; green, decreased expression). (c) Quantitative RT-PCR
analysis of selected gene expression in KLF4 overexpressing Jurkat cells. Data are represented as the mean +/- SEM. (d) Western blot detection of
T cell specific transcription factors in Jurkat cells 48 hours after KLF4 overexpression. (e) KLF4 binds to the promoters of NOTCH1, CXCR4, and BCL2
through regions containing conserved KLF4 consensus sequences. Chromatin immunoprecipitates were performed on cross-linked fragmented
DNAs prepared from Jurkat cells that forcefully expressed KLF4. Eluted DNAs were then analyzed by qPCR performed with primers flanking putative
KLF4-binding sites. The amount of DNA amplified from immunoprecipitated DNAs was normalized to that amplified from input DNA. Data are
represented as the mean +/- SEM.
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KLF4 acts as a tumor suppressor gene or oncogene de-
pending on cellular contexts. A previous report identi-
fied that the KLF4 locus is hypermethylated in T-ALLs
and KLF4 overexpression induced apoptosis in a T-ALL
cell line [21]. However the mechanisms of KLF4-inducedapoptosis and KLF4 targets in T-ALLs remain unclear. In
this study, we used T-ALL as a model system, and demon-
strated that the overexpression of KLF4 induced profound
apoptosis in four human T-ALL cell lines and primary
T-ALL cells in vitro (Figure 6) and increased survival
rates in xenografts (Figure 3b). To systematically uncover
Figure 5 (See legend on next page.)
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Figure 5 KLF4 induces the SUMOylation and degradation of BCL11B. (a) Western blot detection of slowly migrating SUMOylated BCL11B at
the indicated time points. (b) Western blot analysis of BCL11B SUMOylation status in the presence of SUMO-inhibitor treatment in TRE-KLF4 Jurkat
cells. (c) Inhibition of SUMOylation reduces KLF4-induced cell death in the Jurkat cell line. Cells were treated with Dox prior to SUMO inhibitor
(Calyculin A, 50 nM) addition. At the indicated time points after SUMO inhibitor addition, cells were collected and stained with Annexin-V and
7-AAD for apoptosis detection. Top, representative of flow cytometry profiles of TRE-KLF4 Jurkat cells in apoptosis assays. Bottom, summary of
percentages of apoptotic cells (Annexin-V + 7-AAD+) from three independent apoptosis assays. Data are represented as the mean +/- SEM. +Dox
24 h: ** P < 0.01 versus bar 1 (for bar 2), *** P < 0.001 versus bar 1 (for bar 3); +Dox 48 h: ** P < 0.01 versus bar 1 (for bar 2), *** P < 0.001 versus
bar 1 (for bar 3); +Dox 72 h: ** P < 0.01 versus bar 1 (for bar 2), * P < 0.05 versus bar 1 (for bar 3). (d) Inhibition of proteasome reduces KLF4-induced
cell death in the Jurkat cell line. Cells were treated with Dox prior to proteasome inhibitor (MG132, 10 nM) addition. At the indicated time points after
MG132 addition, cells were collected and stained with Annexin-V and 7-AAD for apoptosis detection. Top, representative of flow cytometry profiles of
TRE-KLF4 Jurkat cells in apoptosis assays. Bottom, summary of percentages of apoptotic cells (Annexin-V + 7-AAD+) from three independent apoptosis
assays. Data are represented as the mean +/- SEM. * P < 0.05 versus bar 2 (for bar 1), ** P < 0.01 versus bar 2 (for bar 3).
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performed ChIP assays and global gene expression profile
analyses and identified that KLF4 directly bound to
the promoters of NOTCH1, BCL2, and CXCR4 and
suppressed their expression in T-ALL. In addition, we
demonstrated that KLF4 induced BCL11B degradation by
post-translational modification. Consistently, we found
that KLF4 negatively regulated human T cell development
and homeostasis.
Our studies has clearly demonstrated that KLF4-
induced apoptosis was rescued by overexpression of
BCL2, which was directly suppressed by KLF4. Interest-
ingly, we noticed that the KLF4 expressing Jurkat cells
survived after being injected into immunodeficient mice,
suggesting that the KLF4-induced apoptosis was rescued
in vivo. Consistently, we observed that pro-apoptotic
genes, including BID, BIK, and SIVA1, were downregu-
lated and EP300, RYBP, S100A6, and HSPA2 that have
anti-apoptotic activities were upregulated in KLF4-
expressing Jurkat cells two weeks after being injected
into hosts. The long term survival of Jurkat cells mayFigure 6 Working hypothesis of KLF4 function in T-ALL.
KLF4 induces apoptosis in T-ALL cells by directly suppressing BCL2 by
directly suppressing NOTCH1 transcription and inducing BCL11B
degradation.explain why secondary effects of KLF4 overexpression,
including downregulation of tissue homing genes and
upregulation of cell adhesion and non-T cell determin-
ation genes, were not observed in cultured Jurkat cells
that underwent apoptosis upon KLF4 overexpression
within four days. Further investigation is required to
identify the molecules or proteins in the in vivo micro-
environment that regulated the expression of apoptotic-
related genes. This might be helpful to explain why some
anti-leukemia drug candidates can efficiently eliminate
leukemia cells in vitro but do not work in patients.
The present study also suggested that KLF4 overex-
pression reduced the invasion capacity of T-ALL cells in
hosts. Though there were more Jurkat cells in the Dox-
treated mice, these leukemia-bearing mice survived
much longer than the Dox-untreated group. It is pos-
sible that KLF4-expressing Jurkat cells are less capable
of infiltrating into important organs, such as central ner-
vous system, than normal Jurkat cells. T-ALL patients
are at an increased risk of CNS relapse [16]. CCR7 is the
essential adhesion signal required for the targeting of
T-ALL cells in to the CNS [32]. Here, we found that
CCR7 expression was silenced upon KLF4 overexpres-
sion in Jurkat cells. In addition, we found CXCR4, which
promotes T-ALL cells to infiltrate into liver and lung
tissues in vivo [34], was directly repressed by KLF4 in
Jurkat cells. Furthermore, the expression of TMBIM4
that increased cell adhesion, spreading, and migration
also decreased upon KLF4 overexpression [35]. Down-
regulation of FAT1 might also contribute the loss of
aggressiveness in T-ALL, because knockdown of FAT1
in tumor cells results in a drastic inhibition of cell mi-
gration and invasion [45]. Thus, KLF4 was identified as
a potential repressor of CCR7, CXCR4, TMBIM4, and
FAT1, the pro-metastasis genes, in T-ALL, which might
provide us clues to reduce the invasion capacity of
T-ALL in clinics.
Inhibition of NOTCH1 signaling with GSIs has been
proposed a molecular targeted therapy for T-ALL.
However, GSIs seem to have limited anti-leukemic ac-
tivity in human T-ALL and are associated with severe
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NOTCH1 approaches are in demand for improving T-
ALL therapies. We found that KLF4 directly bound to
NOTCH1 promoter, and suppressed NOTCH1 signaling
and its downstream targets (Figure 6). Although a recent
report showed that Klf4 suppresses Notch signaling in
murine angiogenesis [47], for the first time, we identified
that NOTCH1 was a direct target of KLF4 for transcription
suppression in T-ALLs. Followed by repression of NOTCH
signaling, BCL11B, TCF7, and GATA3, the downstream
targets of NOTCH signaling, were all decreased upon
KLF4 overexpression in T-ALL. In addition, downregula-
tion of T cell surface markers and TCR signaling and
upregulation of non-T cell transcription factors in KLF4-
expressing Jurkat cells could be caused by the silence of
these T cell transcription factors. It will be worthy to de-
velop a chemical approach to initiate endogenous KLF4
expression for inhibition of NOTCH1 signaling in T-ALL.
BCL11B mutations are associated with T cell prolifera-
tive disorders, even though it is arguable whether BCL11B
acts as tumor suppressor or oncogene in T-ALL. The in-
version inv(14)(q11.2q32.31) disrupting the BCL11B locus
was identified in two cases of T-ALL [19], and monoallelic
BCL11B deletions or missense mutations were detected in
9% of T-ALL cases [20]. Furthermore, deletions within
BCL11B were found in irradiation-induced lymphomas in
mice, suggesting that BCL11B is a haploinsufficient tumor
suppressor. However, BCL11B overexpression was found
in the acute type of adult T-cell leukemia/lymphoma and
the majority of T-ALL cell lines [19,48]. It was previously
reported that the downregulation of BCL11B by RNAi
triggered human T-ALL cells to undergo apoptosis
through the BCL2/BCLXL pathway, implicating that
BCL11B acts as an oncogene [49,50]. Consistently, we
found that overexpression of KLF4, an indicated tumor
suppressor gene in T-ALL, promoted the SUMOylation
and degradation of BCL11B in T-ALL, suggesting that
BCL11B acted as an oncogene in T-ALL. However, it re-
mains unclear whether KLF4 directly induces BCL11B
SUMOylation or degradation.
Conclusions
In summary, this study demonstrated that KLF4 directly
repress NOTCH1 and serves as a negative regulator in
human T-ALL and T cell development. Therefore, re-
activation of KLF4 in T-ALL cells may pave a new road
for T cell leukemia therapy.
Methods
Cell culture
All T-ALL cell lines were obtained from the American
Type Culture Collection (ATCC, Manassas, Virginia, USA)
and maintained in RPMI-1640 media (Gibco, New York,
USA) with 10% fetal bovine serum (FBS, Hyclone, Utah,USA). The 293 T cells used for lentivirus packaging were
kindly provided by Professor Duanqing Pei and maintained
in DMEM media (Hyclone, Utah, USA) with 10% FBS.
OP9-DL1 cells were obtained from Dr. J. C. Zuniga
Pflucker (University of Toronto, Toronto, Canada). All
cells were incubated at 37°C in 5% CO2.
All primary samples were obtained with informed
consent for research purposes, and the procedures were
approved by the Research Ethics Board of GIBH. T-ALL
clinical samples were obtained with informed consent
from donors, and related studies were approved by the
Institutional Review Boards at Jinan University Medical
School. In all four T-ALL patients, more than 80% of
PBMC were T-ALL cells.Reagents
All chemicals were from Sigma Chemicals (Munich,
Germany) unless otherwise specified. The pan caspase
inhibitor Z-VAD-FMK was purchased from Beyotime
(Jiangsu, China). Antibodies to BCL11B (ab18465),
NOTCH1 (ab27526), GATA3 (ab61168), TCF7 (ab30961),
KLF4 (ab106629) and SUMO1 (ab32058) were purchased
from Abcam (Cambridge, UK). Anti-FLAG, anti-beta-
ACTIN, and anti-TRAIL antibodies were purchased from
Cell Signal Technologies (Beverly, MA, USA). Antibodies
against BCL2, and BCLXL were obtained from Beyotime
(Jiangsu, China). All secondary antibodies used in this
study were purchased from Sigma (Munich, Germany). A
second-generation lentiviral plasmid and related helper
plasmids were kindly provided by Professor Xiaoping
Chen. The human KLF4 coding sequence was PCR-
amplified (Additional file 4: Table S1) and inserted into
the EcoRI and SpeI restriction sites in the pWPXLD lenti-
viral vector. The correctly ligated plasmid was then se-
quenced and prepared for virus packaging. Lentiviral
vectors encoding the rtTA element and KLF4 driven by a
TRE promoter (TRE-KLF4) were generously provided by
Professor Duanqing Pei.Mice
Animal experiments were performed in the Laboratory
Animal Center of Guangzhou Institutes of Biomedicine
and Health (GIBH), and all animal procedures were
approved by the Animal Welfare Committee of GIBH.
NOD-SCID mice were bred and maintained in SPF-
grade cages and provided with autoclaved food and
water. Mice at 8-12 weeks of age were given 3 Gy of
sublethal irradiation and intravenously injected with
5 × 107 Jurkat cells 6 hours following the irradiation.
Mice were monitored daily for signs of weight loss or
lethargy, and leukocytes from the peripheral blood were
subjected to fluorescence-activated cell sorting (FACS)
analysis.
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The sequencing reads were mapped to the mouse RefSeq-
RNA reference sequence (downloaded from http://
hgdownload.cse.ucsc.edu/downloads) using the FANSe
2 algorithm (http://bioinformatics.jnu.edu.cn/software/
fanse2/) with the parameters − L85 − E3 −U0 − S10 [51].
Reads mapped with tophat2 were associated with genes
using the custom Perl scripts that allowed no more than 2
unmapped bases. Cufflinks (version 2.1.1) were used to
identify reads that were consistent with the annotated
genes download from Ensembl database (http://asia.
ensembl.org/downloads.html) [52]. These genes were
quantified using RPKM method [53]. For small genes
(less than 200 bps) a minimum of 10 mappable reads
were required. The mappable reads were imported into
DEGseq software package to calculate the up-/down-
regulation of genes comparing among PL08, 3 T3, and
PL08-M with a cut-off value that 2-fold ratio in RPKM
and fisher-test FDR of less than 0.05, respectively [54].
ChIP assay
ChIP was performed as previously described in a previ-
ous study [55]. Briefly, 1 × 107 Jurkat cells were trans-
duced by a KLF4-GFP lentivirus, crosslinked with 1%
formaldehyde, and subjected for sonication to generate
500-750 bp DNA fragments. The soluble DNA frag-
ments were immunoprecipitated by anti-KLF4 antibody
(ab106629, Abcam, United Kingdom) or normal rabbit
IgG (ab190495, Abcam, United Kingdom). The immuno-
precipitated DNA was eluted and amplified by quantita-
tive PCR on Bio-Rad CFX96 PCR equipment with the
following primers specific for the NOTCH1, CXCR4, BCL2
or an irrelevant genomic region (βACTIN) (Additional
file 4: Table S1). All ChIP experiments were independ-
ently prepared and repeated at least for three times.
Statistical analysis
Data were analyzed using GraphPad Prism 4 with Stu-
dent’s t-test. P values less than 0.05 were considered sta-
tistically significant.
For detailed information, please find it in Additional file 5.
Additional files
Additional file 1: Supplementary Figures.
Additional file 2: Supplementary Figure Legends.
Additional file 3: Table S2. RNA-sequencing results.
Additional file 4: Table S1. Primers used in this study.
Additional file 5: Supplementary Methods.
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